Skip to main content

TrojanDC

Project description

A Trojan horse rolls into tumour cells, inciting treason

Cancer immunotherapies use the body's own immune system to help fight cancer. Despite tremendous strides and significant resources dedicated to developing novel immunotherapies, currently available treatments are highly effective in only a small proportion of patients. Cancer is a large family of diseases with a complicated diversity of causes and characteristics, significantly increasing the difficulty of achieving personalised and effective treatment. The Swedish start-up Asgard Therapeutics, coordinating the EU-funded TrojanDC project, has developed a Trojan horse to enter tumours and incite revolution, causing cancer cells to become traitors to their kind. Intra-tumoural injection of the TrojanDC gene therapy makes cancer cells become antigen-presenting dendritic cells, bypassing cancer evasion mechanisms in an off-the-shelf, completely personalised therapy system. It could be a silver bullet for any tumour.

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ASGARD THERAPEUTICS AB
Address
Revingegatan 19C 1203
223 59 Lund
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000